Hepatology · NASH/MASH
The ongoing trial of Boehringer Ingelheim's survodutide for NASH/MASH with cirrhosis is significant as it could enhance their portfolio in a competitive therapeutic area. Success in this trial may lead to a stronger market position in the growing liver disease treatment landscape.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/25/2026, 6:34:06 AM
Assessment confidence: 55% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
The ongoing trial of Boehringer Ingelheim's survodutide for NASH/MASH with cirrhosis is significant as it could enhance their portfolio in a competitive therapeutic area. Success in this trial may lead to a stronger market position in the growing liver disease treatment landscape. Assessment grounded in 14 ranked evidence items (3 high-relevance).
Success in this trial could enhance Boehringer Ingelheim's portfolio in hepatology and provide a competitive edge in the treatment of liver diseases. The strongest clinical anchor is LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With Liver Disease Called NASH/MASH Who Have Cirrhosis (ClinicalTrials.gov), entity match (boehringer ingelheim). In Hepatology · NASH/MASH, 0 regulatory and 4 competitive items passed relevance filtering for Boehringer Ingelheim.
The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial. This trial positions Boehringer Ingelheim in the competitive landscape for treatments targeting liver diseases, particularly in the growing NASH/MASH market.
Regulatory risk is concentrated around The trial results will be critical for regulatory approval, influencing the labeling and market entry of survodutide in the treatment of liver diseases..
No evidence in this category.
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With Liver Disease Called NASH/MASH Who Have Cirrhosis
ClinicalTrials.govhigh relevance
Entity match (boehringer ingelheim)
FDA document
View sourceStudy Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceMinimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceHybrid Type 1 Trial of Parent-Based Intervention Addressing Social Media and Adolescent Alcohol Use
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Trial of AI-Powered Text Message Outreach on Well-Child Visit Completion
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRoche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View sourceUK-wide ENDO1000 Study Aims to Advance Endometriosis Diagnosis and Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment
V116 shows safety and immunogenicity in high-risk children for pneumococcal disease
Humanexa Signalsmedium relevance
Moderate corpus alignment
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceElevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceDo subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEffects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceRBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe ongoing trial of Boehringer Ingelheim's survodutide for NASH/MASH with cirrhosis is significant as it could enhance their portfolio in a competitive therapeutic area. Success in this trial may lead to a stronger market position in the growing liver disease treatment landscape.
If successful, survodutide could capture substantial market share in the NASH/MASH segment, potentially leading to significant revenue growth for Boehringer Ingelheim.
The trial results will be critical for regulatory approval, influencing the labeling and market entry of survodutide in the treatment of liver diseases.
Monitor trial results and any announcements regarding efficacy and safety outcomes over the next 4.5 years.
Track for follow-up milestones; no immediate action required.